LFT Lument shares climb despite sharp Q4 2025 EPS miss as investors bet on longterm business improvements NRXP NRX Pharmaceuticals shares climb 352 percent as investors shrug off worse than expected Q4 2025 EPS miss KYMR Kymera Therapeutics posts wider than expected Q4 2025 loss sending shares down 259 percent today